Based on the increased relapse-free survival and good tolerability provided by sorafenib as post-HCT maintenance for FLT3 mutated AML, its use was recommended by the Acute Leukemia Working Party (ALWP)–European Society for Blood and Marrow Transplantation (EBMT) to optimize long-term disease control (7). This evidence concerns the gene FLT3 and acute myeloid leukemia.